Jefferies downgrades Eyepoint stock rating on trial miss
Jefferies downgraded EyePoint Inc. (NASDAQ:EYPT) to Hold, cutting its price target to $1.00 from $8.00. The stock fell 86% to $0.45 after its Phase 3 LUCIA study missed its primary endpoint. The company has $118 million in cash but faces cash burn and extended timelines for other programs. Multiple analysts have downgraded the stock due to trial setbacks.
How this was made
The 30-second read
Why it matters
The downgrade and trial miss sharply reduce near‑term valuation prospects, reinforcing bearish sentiment.
Market read
EyePoint's stock fell 86% after the trial miss; the downgrade amplifies downside risk for investors.
What to watch
Guggenheim maintains a Buy rating, suggesting some analysts still see upside if later data improve.
Background
EyePoint Inc. is a NASDAQ‑listed biotech focused on ophthalmology therapies. The LUCIA Phase 3 trial failure follows a prior miss in the LUGANO study.
Ticker impact
Jefferies downgraded EyePoint Inc. to Hold after its Phase 3 LUCIA trial missed the primary endpoint, causing the stock to plunge 86% to $0.45.
likely further decline as investors price in limited near‑term upside and cash‑runway concerns
Clinical‑trial failure is material for a biotech; the downgrade and sharp price drop indicate heightened sell pressure.
Market effects
Wet AMD biotech sector may see broader risk aversion after another Phase 3 miss.
US biotech indices could face short‑term pressure.
Limited to investors tracking ophthalmology therapeutics and small‑cap biotech.
Counterpoint
If the diabetic macular edema readout in 2027 is positive, the stock could rebound on long‑term potential.
Key entities
- AnalystJefferies
Downgraded EyePoint to Hold and cut price target to $1.00.
- AnalystGuggenheim
Maintained a Buy rating despite the trial miss.
